Neurogenomics – News and Features

Sequenom develops a noninvasive test for Trisomy 21, Down syndrome, that will incorporate multiple RNA fetal markers.

Sequenom has announced the approval of a protocol by the Institutional Review Board (IRB) at San Diego-based Sharp HealthCare.

The National Institutes of Health has developed a research plan to advance understanding of Down syndrome and speed development of new treatments for the condition.

Researchers focuses on how Fragile X syndrome affects communication between cells in a region of the brain that is involved in learning and memory.

A breakdown in proper cell development has been shown to cause brain-specific stem cells to become starter seeds for aggressive brain tumors called glioblastoma multiforme.

Researchers are uncovering how brain cells are affected in Fragile X syndrome, the most common cause of inherited mental retardation.

The noninvasive prenatal test based on Sequenom's SEQureDx™ Technology for cell free fetal nucleic acid assessment.

Boosting an exercise-related gene in the brain works as a powerful anti-depressant in mice, according to a Yale School of Medicine report.

A variant of a gene involved in communication among brain cells has a direct influence on alcohol consumption in mice, researchers say.

A group of the nation’s leaders in stem cell biology announced formation of a new biotechnology company developing drugs to control cell fate.